Literature DB >> 28330429

Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone.

Benjamin Wong1, Michael W Perkins1, Justin Tressler1, Ashley Rodriguez1, Jennifer Devorak1, Alfred M Sciuto1.   

Abstract

This study examined the real-time exposure-response effects of aerosolized carfentanil (CRF) on opioid-induced toxicity, respiratory dynamics and cardiac function in mice. Unrestrained, conscious male CD-1 mice (25-30 g) were exposed to 0.4 or 4.0 mg/m3 of aerosolized CRF for 15 min (Ct = 6 or 60 mg min/m3) in a whole-body plethysmograph chamber. Minute volume (MV), core body temperature (Tc), mean arterial blood pressure (MAP) and heart rate (HR) were evaluated in animals exposed to CRF or sterile H2O. Loss of consciousness and Straub tail were observed in before 1 min following initiation of exposure to 6 or 60 mg min/m3 of CRF. Clinical signs of opioid-induced toxicity were observed in a dose-dependent manner. Exposure to 6 or 60 mg min/m3 of CRF resulted in significant decrease in MV as compared to the controls. MAP, HR and Tc decreased 24 h in animals exposed to either 6 or 60 mg min/m3 of CRF as compared to the controls. Post-exposure administration of naloxone (NX, 0.05 mg/kg, i.m.) did not increase the MV of animals exposed to CRF to control levels within 24 h, but decreased clinical signs of opioid-induced toxicity and the duration of respiratory depression. This is the first study to evaluate real-time respiratory dynamics and cardiac function during exposure and up to 24 h post-exposure to CRF. The evaluation of toxicological signs and respiratory dynamics following exposure to CRF will be useful in the development of therapeutic strategies to counteract the ongoing threat of abuse and overuse of opioids and their synthetic variants.

Entities:  

Keywords:  Cardiac function; carfentanil; inhalation exposure; naloxone; respiratory dynamics; respiratory toxicology

Mesh:

Substances:

Year:  2017        PMID: 28330429     DOI: 10.1080/08958378.2017.1282065

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  7 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)-August 6/7, 2019.

Authors:  David T Yeung; Kristopher J Bough; Jill R Harper; Gennady E Platoff
Journal:  J Med Toxicol       Date:  2019-12-18

3.  Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated.

Authors:  Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley
Journal:  Biochem Pharmacol       Date:  2021-10-19       Impact factor: 6.100

4.  First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass.

Authors:  Marthe M Vandeputte; Nick Verougstraete; Donna Walther; Grant C Glatfelter; Jeroen Malfliet; Michael H Baumann; Alain G Verstraete; Christophe P Stove
Journal:  Arch Toxicol       Date:  2022-04-21       Impact factor: 6.168

5.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

6.  Higher doses of naloxone are needed in the synthetic opiod era.

Authors:  Ronald B Moss; Dennis J Carlo
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-02-18

Review 7.  Metabolic clearance of select opioids and opioid antagonists using hepatic spheroids and recombinant cytochrome P450 enzymes.

Authors:  Wing Y Tuet; Samuel A Pierce; Matthieu Conroy; Justin N Vignola; Justin Tressler; Robert C diTargiani; Bryan J McCranor; Benjamin Wong
Journal:  Pharmacol Res Perspect       Date:  2022-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.